Ghent University Academic Bibliography

Advanced

Vagus nerve stimulation for depression: efficacy and safety in a European study

T. E. Schlaepfer, C. Frick, A. Zobel, W. Maier, I. Heuser, M. Bajbouj, V. O'Keane, C. Corcoran, R. Adolfsson and M. Trimble, et al. (2008) PSYCHOLOGICAL MEDICINE. 38(5). p.651-661
abstract
Background. Vagus nerve stimulation (VNS) therapy is associated with a decrease in seizure frequency in partial-onset seizure patients. Initial trials suggest that it may be an effective treatment, with few side-effects, for intractable depression. Method. An open, uncontrolled European multi-centre study (D03) of VNS therapy was conducted, in addition to stable pharmacotherapy, in 74 patients with treatment-resistant depression (TRD). Treatment remained unchanged for the first 3 months; in the subsequent 9 months, medications and VNS dosing parameters were altered as indicated clinically. Results. The baseline 28-item Hamilton Depression Rating Scale (HAMD-28) score averaged 34. After 3 months of VNS, response rates (>= 50% reduction in baseline scores) reached 37% and remission rates (HAMD-28 score <10) 17%. Response rates increased to 53% after 1 year of VNS, and remission rates reached 33%. Response was defined as sustained if no relapse occurred during the first year of VNS after response onset; 44% of patients met these criteria. Median time to response was 9 months. Most frequent side-effects were voice alteration (63% at 3 months of stimulation) and coughing (23 %). Conclusions. VNS therapy was effective in reducing severity of depression; efficacy increased over time. Efficacy ratings were in the same range as those previously reported from a USA study using a similar protocol; at 12 months, reduction of symptom severity was significantly higher in the European sample. This might be explained by a small but significant difference in the baseline HAMD-28 score and the lower number of treatments in the current episode in the European study.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
keyword
vagus nerve stimulation, brain stimulation, TRIAL, PLACEBO, MECHANISMS, SEIZURES, EPILEPSY, THERAPY, LONG-TERM, major depression, treatment resistance, MAJOR DEPRESSION, TREATMENT-RESISTANT DEPRESSION, CEREBRAL-BLOOD-FLOW
journal title
PSYCHOLOGICAL MEDICINE
Psychol. Med.
volume
38
issue
5
pages
651 - 661
Web of Science type
Article
Web of Science id
000255474600007
JCR category
PSYCHOLOGY, CLINICAL
JCR impact factor
4.718 (2008)
JCR rank
4/88 (2008)
JCR quartile
2 (2008)
ISSN
0033-2917
DOI
10.1017/S0033291707001924
language
English
UGent publication?
yes
classification
A1
id
745526
handle
http://hdl.handle.net/1854/LU-745526
date created
2009-09-09 09:03:18
date last changed
2015-06-17 11:17:07
@article{745526,
  abstract     = {Background. Vagus nerve stimulation (VNS) therapy is associated with a decrease in seizure frequency in partial-onset seizure patients. Initial trials suggest that it may be an effective treatment, with few side-effects, for intractable depression.

Method. An open, uncontrolled European multi-centre study (D03) of VNS therapy was conducted, in addition to stable pharmacotherapy, in 74 patients with treatment-resistant depression (TRD). Treatment remained unchanged for the first 3 months; in the subsequent 9 months, medications and VNS dosing parameters were altered as indicated clinically.

Results. The baseline 28-item Hamilton Depression Rating Scale (HAMD-28) score averaged 34. After 3 months of VNS, response rates ({\textrangle}= 50\% reduction in baseline scores) reached 37\% and remission rates (HAMD-28 score {\textlangle}10) 17\%. Response rates increased to 53\% after 1 year of VNS, and remission rates reached 33\%. Response was defined as sustained if no relapse occurred during the first year of VNS after response onset; 44\% of patients met these criteria. Median time to response was 9 months. Most frequent side-effects were voice alteration (63\% at 3 months of stimulation) and coughing (23 \%).

Conclusions. VNS therapy was effective in reducing severity of depression; efficacy increased over time. Efficacy ratings were in the same range as those previously reported from a USA study using a similar protocol; at 12 months, reduction of symptom severity was significantly higher in the European sample. This might be explained by a small but significant difference in the baseline HAMD-28 score and the lower number of treatments in the current episode in the European study.},
  author       = {Schlaepfer, T. E. and Frick, C. and Zobel, A. and Maier, W. and Heuser, I. and Bajbouj, M. and O'Keane, V. and Corcoran, C. and Adolfsson, R. and Trimble, M. and Rau, H. and Hoff, H. -J. and Padberg, F. and Mueller-Siecheneder, F. and Audenaert, Kurt and Van den Abbeele, D. and Matthews, K. and Christmas, D. and Stanga, Z. and Hasdemir, M.},
  issn         = {0033-2917},
  journal      = {PSYCHOLOGICAL MEDICINE},
  keyword      = {vagus nerve stimulation,brain stimulation,TRIAL,PLACEBO,MECHANISMS,SEIZURES,EPILEPSY,THERAPY,LONG-TERM,major depression,treatment resistance,MAJOR DEPRESSION,TREATMENT-RESISTANT DEPRESSION,CEREBRAL-BLOOD-FLOW},
  language     = {eng},
  number       = {5},
  pages        = {651--661},
  title        = {Vagus nerve stimulation for depression: efficacy and safety in a European study},
  url          = {http://dx.doi.org/10.1017/S0033291707001924},
  volume       = {38},
  year         = {2008},
}

Chicago
Schlaepfer, T. E., C. Frick, A. Zobel, W. Maier, I. Heuser, M. Bajbouj, V. O’Keane, et al. 2008. “Vagus Nerve Stimulation for Depression: Efficacy and Safety in a European Study.” Psychological Medicine 38 (5): 651–661.
APA
Schlaepfer, T. E., Frick, C., Zobel, A., Maier, W., Heuser, I., Bajbouj, M., O’Keane, V., et al. (2008). Vagus nerve stimulation for depression: efficacy and safety in a European study. PSYCHOLOGICAL MEDICINE, 38(5), 651–661.
Vancouver
1.
Schlaepfer TE, Frick C, Zobel A, Maier W, Heuser I, Bajbouj M, et al. Vagus nerve stimulation for depression: efficacy and safety in a European study. PSYCHOLOGICAL MEDICINE. 2008;38(5):651–61.
MLA
Schlaepfer, T. E., C. Frick, A. Zobel, et al. “Vagus Nerve Stimulation for Depression: Efficacy and Safety in a European Study.” PSYCHOLOGICAL MEDICINE 38.5 (2008): 651–661. Print.